NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SOUTH SAN FRANCISCO, Calif., December 17, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., December 16, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the...
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
– Initial clinical data expected mid-2026 – South San Francisco, Calif. — December 3, 2025 — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),...
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board)...
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at World ADC and SITC,...
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., November 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC...
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
SOUTH SAN FRANCISCO, Calif., September 29, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize...
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to...
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
SOUTH SAN FRANCISCO, Calif., July 22, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the...